Good thing is that after BLA submission and closing of investigative mono trial, cashburn will go down significantly. On the other hand, without non-dilutive funds, it will be difficult to start mono pivotal, unless they want to raise another 15m or so at these ridiculuously depressed prices. A deal must be closed by year-end; it's been long enough, honestly.

If they can't attract a BP (or mid-sized pharma) currently not involved in HIV that would obviously profit massively by entering the HIV business and attacking the current market owners, on favourable terms, they are doing something wrong IMO. I can see why Gilead and other established players could be hesitating until mono is approved , but not why other non-HIV companies wouldn't be...